Comparative Pharmacology
Head-to-head clinical analysis: AMINOSYN II 15 IN PLASTIC CONTAINER versus AMINOSYN II 5.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AMINOSYN II 15 IN PLASTIC CONTAINER versus AMINOSYN II 5.
AMINOSYN II 15% IN PLASTIC CONTAINER vs AMINOSYN II 5%
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Provides essential amino acids for protein synthesis, serving as substrates for nitrogen balance and tissue repair.
Aminosyn II 5% provides essential and non-essential amino acids for protein synthesis, serving as substrates for nitrogen balance and tissue repair. It supports metabolic processes in patients unable to maintain adequate nutrition enterally.
Intravenous infusion: 1.0 to 2.0 g amino acids/kg/day, maximum 125 mL/hour (3 g amino acids/kg/day).
Intravenous infusion via central line, initial rate 50 mL/hour, increase by 25 mL/hour every 24 hours to goal rate of 1-2 mL/kg/hour (maximum 125 mL/hour). Total daily dose: 1.5-2.0 g/kg/day of amino acids (equivalent to 30-40 mL/kg/day).
None Documented
None Documented
Amino acids: rapid clearance, half-life 0.5-2 hours depending on individual and metabolic state. Clinical context: continuous infusion maintains steady state.
Not applicable as a single entity; individual amino acids have variable half-lives (e.g., 10-30 min for most), reflecting rapid distribution and metabolism. Clinical context: continuous infusion maintains steady state.
Renal: amino acids are filtered and reabsorbed; excess nitrogen is excreted as urea in urine. <5% fecal.
Renal elimination of amino acids is minimal under normal conditions; excess amino acids are metabolized, and nitrogen is excreted as urea (renal, ~80-90%) and ammonia. Biliary/fecal excretion negligible.
Category C
Category C
Amino Acid Solution
Amino Acid Solution